Please use this identifier to cite or link to this item:
|Title:||Chemoprevention of breast cancer among women at elevated risk as defined by Gail Score|
Brincat, Mark P.
Cancer -- Chemoprevention
Breast -- Cancer
|Publisher:||Edizioni Minerva Medica|
|Citation:||Micallef, S., Micallef, D., Schembri-Wismayer, P., Brincat, M. P., & Calleja-Agius, J. (2015). Chemoprevention of breast cancer among women at elevated risk as defined by Gail Score. Minerva Ginecologica, 67(4), 335-352.|
|Abstract:||The risk of an individual woman to develop breast cancer over a 5-year period can be estimated using the Gail Model. The risk factors included in this model effectively classify patients into two different subgroups. One subgroup comprises patients at increased risk because of increased exposure to estrogen. These women are more likely to benefit from endocrine chemopreventive therapies, namely selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs). The second subgroup comprises women who have inherited genetic mutations that predispose them to breast cancer. Chemoprevention in these patients is more likely to be achieved by novel agents, such as lapatinib, gefitinib, fenretinide, rexinoids and poly(ADP-ribose) polymerase (PARP) -inhibitors.|
|Appears in Collections:||Scholarly Works - FacM&SAna|
Files in This Item:
|986.91 kB||Adobe PDF||View/Open Request a copy|
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.